Fetal biometry following in-utero exposure to dolutegravir-based or efavirenz-based antiretroviral therapy.

Szczegóły

Tytuł:: Fetal biometry following in-utero exposure to dolutegravir-based or efavirenz-based antiretroviral therapy.
Autorzy:: Banda FM; Department of Paediatrics and Adolescent Health, Faculty of Medicine, University of Botswana.
Powis KM; Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health.; Departments of Internal Medicine and Pediatrics, Massachusetts General Hospital, Boston, Massachusetts.
Sun S; Department of Pediatrics, Ann and Robert H. Lurie Children's Hospital of Chicago.
Makhema J; Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Masasa G; Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Yee LM; Department of Obstetrics and Gynecology.
Jao J; Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.; Department of Pediatrics.; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Źródło:: AIDS (London, England) [AIDS] 2020 Dec 01; Vol. 34 (15), pp. 2336-2337.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural
Język:: English
Imprint Name(s):: Publication: 1998- : London, England : Lippincott Williams & Wilkins
Original Publication: London : Gower Academic Journals, c1987-
MeSH Terms:: Alkynes*/administration & dosage
Alkynes*/adverse effects
Benzoxazines*/administration & dosage
Benzoxazines*/adverse effects
Cyclopropanes*/administration & dosage
Cyclopropanes*/adverse effects
Fetus*/anatomy & histology
Fetus*/diagnostic imaging
Fetus*/drug effects
HIV Infections*/drug therapy
Heterocyclic Compounds, 3-Ring*/administration & dosage
Heterocyclic Compounds, 3-Ring*/adverse effects
Oxazines*/administration & dosage
Oxazines*/adverse effects
Piperazines*/administration & dosage
Piperazines*/adverse effects
Pregnancy Complications, Infectious*/drug therapy
Pregnancy Complications, Infectious*/virology
Pyridones*/administration & dosage
Pyridones*/adverse effects
Biometry ; Female ; HIV Integrase Inhibitors/administration & dosage ; HIV Integrase Inhibitors/adverse effects ; Humans ; Pregnancy ; Reverse Transcriptase Inhibitors/administration & dosage ; Reverse Transcriptase Inhibitors/adverse effects ; Ultrasonography, Prenatal
References:: Lancet. 2014 Sep 6;384(9946):869-79. (PMID: 25209488)
Obstet Gynecol. 2016 Dec;128(6):e241-e256. (PMID: 27875472)
Lancet Glob Health. 2018 Jul;6(7):e804-e810. (PMID: 29880310)
Grant Information:: R01 DK109881 United States DK NIDDK NIH HHS
Substance Nomenclature:: 0 (Alkynes)
0 (Benzoxazines)
0 (Cyclopropanes)
0 (HIV Integrase Inhibitors)
0 (Heterocyclic Compounds, 3-Ring)
0 (Oxazines)
0 (Piperazines)
0 (Pyridones)
0 (Reverse Transcriptase Inhibitors)
DKO1W9H7M1 (dolutegravir)
JE6H2O27P8 (efavirenz)
Entry Date(s):: Date Created: 20200910 Date Completed: 20210217 Latest Revision: 20220809
Update Code:: 20240105
PubMed Central ID:: PMC9359613
DOI:: 10.1097/QAD.0000000000002674
PMID:: 32910067
: Czasopismo naukowe

Informacja